671-P: Patterns of Sensor-Detected Hypoglycemia in Long-Duration CGM Data from a Diabetes Registry

Abstract

Compared to time below range less is known about the frequency and temporal distribution of hypoglycemic episodes in CGM data. Pooled analysis of long-duration CGM data from a diabetes registry allows for large-scale exploration of sensor-detected hypoglycemic episodes (SDHE) . 66 patients with T1D used CGM over 365.7 (340.6-392.5) days (24.530 days total) . In addition to time below range (TBR) , we explored frequency of SDHE >15 minutes at <70, <54 and 40 mg/dl by time of day and sensor runtime (30 days) as well as glycemic control by pooled individual days (12AM-12AM) . TBR was 5.4% (<70) , 1.9% (<54) and 0.7% (=40) . 24.7% of SDHE<70 occurred at nighttime (0-6am = 25% of hours/day) . SDHE<54 and SDHE=40 had a nightly surplus with 34.4% and 41.5%, respectively. Number of daily SDHE<70 slightly decreased over the first month and was more uniform across subjects. Numbers of SHDE<54 and SHDE=40 are more varied, and the latter increased over time. Pooled CGM days showed a decrease and greater variance in glucose levels during the night, a surplus of nightly readings at 40mg/dl and a drop in glucose around noon. Focus on SHDE and individual days showed similar patterns to TBR regarding the surplus and variability of nightly low readings. The greater variability and the increase of SHDE=40 over 30 days while SDHE<70 remained stable suggest that sensor lifetime may be a confounder. Overall, SDHE is a valuable addition to TBR. Disclosure P.M.Baumann: None. D.A.Hochfellner: None. M.Cigler: None. R.Siegl: None. T.Poettler: None. J.K.Mader: Advisory Panel; Abbott Diabetes, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, Speaker's Bureau; Abbott Diabetes, Eli Lilly and Company, Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, Servier Laboratories, Stock/Shareholder; decide Clinical Software GmbH. Funding "This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement 777460. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF) , The Leona M. and Harry B. Helmsley Charitable Trust."